D3L-002

D3L-002 is a bispecific monoclonal antibody developed by D3 Bio (Wuxi) that targets both TIGIT and PVRIG immune checkpoint receptors. It is designed to simultaneously bind to the extracellular domains of human TIGIT and PVRIG, effectively blocking the interactions between TIGIT/PVR and PVRIG/PVRL2. This dual blockade restores the function of exhausted T cells and NK cells, leading to enhanced anti-tumor activity in preclinical models. The antibody has a symmetric IgG-single-chain variable fragment (scFv) structure, demonstrates high binding affinity for its targets, and shows cross-reactivity with cynomolgus homologs. Preclinical studies indicate that D3L-002 can deplete regulatory T cells (Treg), reinvigorate CD8+ T cell proliferation in the tumor microenvironment, enhance NK cell cytotoxicity, and may overcome resistance to current immune checkpoint blockade therapies. Its primary indication is for solid tumors within oncology[1][4][6].